Valeant, Progenics release RELISTOR Tablets for OIC
The Food and Drug Administration approved RELISTOR Tablets in July to treat opioid-induced constipation (OIC) in adults who are being treated with opioid-based medicines for cancer pain.
"We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC," Valeant CEO Joseph Papa said. "This new method of delivery for RELISTOR offers health care professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant's continued commitment to delivering innovative products that improve people's lives."
The RELISTOR Tablets were also the focus of poster presentations in September, at PAINWeek in Las Vegas on September and by University of Miami Health System Professor of Pathology Dr. Steven Simon.